Research summary ·
Refining the TCGA Framework: The Pivotal Role of Targeted Next-Generation Sequencing in Resolving Diagnostic Ambiguities in Endometrial Cancer-Systematic Review.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review looked at gene sequencing in endometrial cancer. It focused on targeted next-generation sequencing, or NGS. The review asked if NGS can sharpen a molecular model called TCGA. The model sorts tumors into subtypes. The review used 11 studies from PubMed, Scopus and Embase, mainly from 2019 to 2025.
What they found
NGS was key for finding POLE gene changes. Older tests cannot spot these. NGS classified tumors with more than one molecular trait. It needs more time and resources. It gives a more objective and repeatable result. Its panels sorted patients into prognostic groups. Agreement between NGS and older tests varied by platform and gene. NGS testing of inherited genes found Lynch syndrome in some patients. Panels also found gene changes relevant to PARP inhibitor use.
What it means for patients
The authors say NGS plus older tests give the most accurate diagnosis. They say this cuts diagnostic errors. They say it gives a basis for personal treatment decisions.
Why it is not certain yet
The review had only 11 studies. Agreement between tests varied by platform and gene target. Sequencing needs more time and resources. The abstract does not give patient outcomes after care guided by NGS.
Source
Refining the TCGA Framework: The Pivotal Role of Targeted Next-Generation Sequencing in Resolving Diagnostic Ambiguities in Endometrial Cancer-Systematic Review.
PubMed · PMID 42883850We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Endometrial cancer publications